Estrella Immunopharma, Inc. (NASDAQ:ESLA – Get Free Report) saw a significant growth in short interest in July. As of July 15th, there was short interest totalling 19,100 shares, a growth of 8.5% from the June 30th total of 17,600 shares. Based on an average trading volume of 17,600 shares, the short-interest ratio is currently 1.1 days. Approximately 0.2% of the company’s stock are short sold.
Institutional Trading of Estrella Immunopharma
An institutional investor recently bought a new position in Estrella Immunopharma stock. ATW Spac Management LLC bought a new position in Estrella Immunopharma, Inc. (NASDAQ:ESLA – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 40,000 shares of the company’s stock, valued at approximately $44,000. ATW Spac Management LLC owned about 0.11% of Estrella Immunopharma as of its most recent filing with the Securities and Exchange Commission. 0.35% of the stock is currently owned by institutional investors.
Estrella Immunopharma Stock Down 22.4 %
Shares of NASDAQ ESLA traded down $0.45 during midday trading on Tuesday, reaching $1.56. 164,140 shares of the company’s stock were exchanged, compared to its average volume of 60,249. Estrella Immunopharma has a 52-week low of $0.81 and a 52-week high of $33.00. The business’s fifty day moving average price is $1.14 and its two-hundred day moving average price is $1.12.
About Estrella Immunopharma
Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.
Featured Stories
- Five stocks we like better than Estrella Immunopharma
- 3 REITs to Buy and Hold for the Long Term
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- How to Invest in Insurance Companies: A GuideĀ
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Estrella Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Estrella Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.